SanBio : Notice Regarding Change of Representative Director
April 14, 2021 at 02:05 am EDT
Share
April 14, 2021
Company name:
SanBio Co., Ltd.
Representative:
Keita Mori, Representative Director
and President
(TSE Mothers Code: 4592)
Contact:
Yoshihiro Kakutani, Corporate Officer
of Management Administration
(TEL. +81-3-6264-3481)
Notice Regarding Change of Representative Director
(Additional Appointment)
At a Board of Directors' meeting held on April 14, 2021, the Company resolved to approve the appointment of an additional representative director as follows.
1. Reason for change (additional appointment)
The Company decided to appoint an additional representative director and thereby adopt a three-member representative director structure to promote the development of the SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) as a whole and strengthen its business structure.
2. Details of change (candidate for new representative director)
Current position
New position
Akihiro Tsujimura
Executive Vice President and
Representative Director,
COO
Executive Vice President, and
COO
<SanBio, Inc.>
Current position
New position
Akihiro Tsujimura
CEO
CEO (no change)
3. Career summary of Mr. Akihiro Tsujimura
Name
Career summary
1992
Joined Nichimen Corp. (current Sojitz Corp.)
2001
President & CEO, Biaxis Packaging Sales Inc., an
overseas joint venture of Nichimen
Akihiro Tsujimura
2004
Joined Santen Pharmaceutical Co., Ltd.
(DOB: Dec. 26, 1967)
2012
Corporate Officer, Santen Pharmaceutical/ President
& CEO, Santen Inc.
1
2015
Senior Corporate Officer and Head of Asia Business,
Santen Pharmaceutical
2016
Executive Corporate Officer and Head of Corporate
Development Division, in charge of Asia and North
America Businesses, Santen Pharmaceutical/ President
& CEO, Santen Inc.
2017
Director, Santen Pharmaceutical
2018
Joined SanBio Co., Ltd.
Senior Managing Executive Officer, SanBio/ CEO,
SanBio, Inc.
2019
Executive Officer and Senior Managing Director,
SanBio/ CEO, SanBio, Inc.
2020
Executive Vice President and COO, SanBio/ CEO,
SanBio, Inc.
4. Scheduled date of change
Mr. Akihiro Tsujimura will be appointed as representative director upon approval at the Eighth General Meeting of Shareholders to be held on April 28, 2021, and will assume his post with the resolution of the Board of Directors at a meeting to be held after the conclusion of the General Meeting of Shareholders.
For details regarding the General Meeting of Shareholders, Please refer to the "Convocation Notice for the Eighth General Meeting of Shareholders" (Japanese only) published on April 13, 2021.
2
Attachments
Original document
Permalink
Disclaimer
SanBio Co. Ltd. published this content on 14 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 April 2021 06:04:06 UTC.
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).